|
5GRN
Crystal structure of PDGFRA in Complex with WQ-C-159
Deposited 2016-08-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
550–696(147 aa)
Fragment:UNP residues 550-696 and 769-973
Chain A
769–973(205 aa)
Fragment:UNP residues 550-696 and 769-973
|
Not recorded
|
748 N-[2-(dimethylamino)ethyl]-N-[[4-[[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]carbamoyl]phenyl]methyl]pyridine-3-carboxamide × 1
CL CHLORIDE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2M KCl, 20% PEG 3350, pH 7.0
|
Resolution 1.77 Å
R-free 0.179
|
|
5K5X
Crystal structure of human PDGFRA
Deposited 2016-05-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
550–696(147 aa)
Fragment:UNP residues 550-696,769-973
Chain A
769–973(205 aa)
Fragment:UNP residues 550-696,769-973
|
Not recorded
|
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.1M HEPES pH7.5, 1.6M (NH4)2SO4, 0.1M NaCl
|
Resolution 2.17 Å
R-free 0.224
|
|
6A32
Crystal structure of PDGFRA kinase domain mutant T674I
Deposited 2018-06-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
550–696(147 aa)
Chain A
769–973(205 aa)
|
Mutation:T674I
Mutation:T674I
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.1M Bis-Tris pH 5.5, 27% PEG 3350
|
Resolution 1.87 Å
R-free 0.240
|
|
6JOI
Crystal structure of PDGFRA T674I in complex with crenolanib by co-crystallization
Deposited 2019-03-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
550–696(147 aa)
Chain A
769–973(205 aa)
|
Mutation:T674I
Mutation:T674I
|
6T2 1-(2-{5-[(3-Methyloxetan-3-yl)methoxy]-1H-benzimidazol-1-yl}quinolin-8-yl)piperidin-4-amine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.1M NaCl, 0.1M Tris pH 8.0, 15% PEG 4000
|
Resolution 3.10 Å
R-free 0.244
|
|
6JOJ
Crystal structure of PDGFRA T674I in complex with crenolanib by soaking
Deposited 2019-03-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
550–696(147 aa)
Chain A
769–973(205 aa)
|
Not recorded
|
6T2 1-(2-{5-[(3-Methyloxetan-3-yl)methoxy]-1H-benzimidazol-1-yl}quinolin-8-yl)piperidin-4-amine × 1
SO4 SULFATE ION × 2
CL CHLORIDE ION × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.1M HEPES pH6.9, 1.6M (NH4)2SO4, 0.1M NaCl
|
Resolution 2.60 Å
R-free 0.233
|
|
6JOK
Crystal structure of PDGFRA in complex with sunitinib by soaking
Deposited 2019-03-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
550–696(147 aa)
Chain A
769–973(205 aa)
|
Not recorded
|
B49 N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carbo xamide × 1
CL CHLORIDE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.1M HEPES pH6.9, 1.6M (NH4)2SO4, 0.1M NaCl
|
Resolution 3.80 Å
R-free 0.282
|
|
6JOL
Crystal structure of PDGFRA in complex with imatinib by co-crystallization
Deposited 2019-03-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
550–696(147 aa)
Chain A
769–973(205 aa)
|
Not recorded
|
STI 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.1M Sodium citrate pH4.5, 20% PEG 4000
|
Resolution 1.90 Å
R-free 0.236
|
|
7RAM
Cryo-EM Structure of the HCMV gHgLgO Trimer Derived from AD169 and TR strains in complex with PDGFRalpha
Deposited 2021-07-02
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain D
1–524(524 aa)
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5;300mM NaCl and 20mM HEPES7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.43 Å
|
|
8PQH
PDGFRA T674I mutant kinase domain in complex with avapritinib
Deposited 2023-07-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
550–696(147 aa)
Chain A
769–973(205 aa)
|
Mutation:T674I
Mutation:T674I
|
9JI Avapritinib × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293.15 K;10 mg/mL, 13% PEG3350, 200 mM KCl
|
Resolution 2.50 Å
R-free 0.249
|
|
8PQI
PDGFRA T674I mutant kinase domain in complex with avapritinib derivative 9
Deposited 2023-07-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
550–696(147 aa)
Chain A
769–973(205 aa)
|
Mutation:T674I
Mutation:T674I
|
9OO (1~{S})-~{N}-ethyl-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293.15 K;5 mg/mL, 5% PEG3350, 200 mM KCl
|
Resolution 2.60 Å
R-free 0.254
|
|
8PQJ
PDGFRA wild-type kinase domain
Deposited 2023-07-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
550–696(147 aa)
Chain A
769–973(205 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;285.15 K;10 mg/mL, 15% PEG3350, 100 mM Bis-Tris-Propane, pH 7.5
|
Resolution 1.82 Å
R-free 0.215
|
|
8PQK
APO crystal structure of PDGFRA-T674I kinase domain
Deposited 2023-07-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
550–696(147 aa)
Chain A
769–973(205 aa)
|
Mutation:T674I
Mutation:T674I
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293.15 K;10 mg/mL, 22% PEG3350, 100 mM Bis-Tris-Propane, pH 7.5
|
Resolution 2.00 Å
R-free 0.222
|
|
9GZH
PDGFRA-T674I in complex with covalent ponatinib derivative 19
Deposited 2024-10-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
550–973(424 aa)
|
Mutation:T674I
|
A1IRC 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-~{N}-[4-(propanoylamino)-3-(trifluoromethyl)phenyl]benzamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293.15 K;5 mg/mL, 18% PEG3350, 100 mM KCl
|
Resolution 2.20 Å
R-free 0.215
|